NDA 203567 · Bausch
Jublia
Efinaconazole · Topical · Azole Antifungal
NovelLast checked: Nov 20, 2026Latest source record: Mar 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jun 6, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
7
1 Phase 3, 0 recruiting
FAERS reports
1,962
727 serious, 108 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2025.
JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . JUBLIA is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . (1)
Mechanism: JUBLIA topical solution is an azole antifungal [ see Clinical Pharmacology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 26, 2020 Supplement 9 · Efficacy LetterLabel
- Jun 6, 2014 Original approval · Type 1 - New Molecular Entity NovelReviewLabelSummary Review
1 products under this application
- JUBLIA · EFINACONAZOLE 10% · SOLUTION, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Efinaconazole" as an intervention, any sponsor and status, largest first.
- A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the ToenailsPivotal-lookingNot yet recruiting
Onyx AxiomAmgen (AMGN)
NCT07382427 · 200 participants (planned) · Start Mar 2026 · Primary completion Jan 2028
Drug: 2.4% Topical Terbinafine; 10% Topical Efinaconazole · For: Onychomycosis of Toenail
Dong-A ST Co., Ltd.Industry
NCT03280927 · 97 participants · Start Nov 10, 2017 · Primary completion Jan 22, 2020
Drug: Jublia® · For: Mild to Moderate Onychomycosis Due to Dermatophyte
Sites: Seoul, South Korea
Bausch Health Americas, Inc.Industry
NCT02812771 · 62 participants · Start Aug 4, 2016 · Primary completion Jan 14, 2019
Drug: Efinaconazole · For: Onychomycosis
Sites: Birmingham, Alabama; Fountain Valley, California; Santa Rosa, California · 10 sites in all
- Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic PatientsPivotal-lookingCompleted
Western University of Health SciencesAcademic, hospital or other
NCT03168841 · 40 participants · Start Jun 6, 2017 · Primary completion Jan 9, 2019
Drug: Efinaconazole Topical · For: Onychomycosis
Sites: Pomona, California
University of Alabama at BirminghamAcademic, hospital or other
NCT03098615 · 19 participants · Start Sep 2015 · Primary completion May 2017
Drug: Jublia (Efinaconazole 10% Topical Solution) · For: Onychomycosis; Dermatophytosis
Sites: Birmingham, Alabama
University of Alabama at BirminghamAcademic, hospital or other
NCT03110029 · 13 participants · Start Sep 2015 · Primary completion May 2017
Drug: Efinaconazole 10% Topical Application Solution [JUBLIA] · For: Onychomycosis of Toenail
Sites: Birmingham, Alabama
University of Alabama at BirminghamAcademic, hospital or other
NCT03022916 · 5 participants · Start Sep 2015 · Primary completion Sep 2017
Drug: Nail Polish + Efinaconazole Solution; Base Coat + Nail Polish + Top Coat + Efinaconazole Solution and 1 more · For: Evaluation of Jublia on Nail Polish With Healthy Toenails
Sites: Birmingham, Alabama
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective423
- fatigue244
- pain234
- headache214
- asthenia209
- drug hypersensitivity183
- oedema peripheral180
- anaemia172
- pyrexia170
- product dose omission issue166
- asthma163
- tremor163
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 27 |
| 2015 | 314 |
| 2016 | 329 |
| 2017 | 163 |
| 2018 | 133 |
| 2019 | 99 |
| 2020 | 105 |
| 2021 | 131 |
| 2022 | 119 |
| 2023 | 163 |
| 2024 | 154 |
| 2025 | 133 |
| 2026 | 92 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jublia (Efinaconazole)
2024 spending
$119M
Beneficiaries
35,400
101,398 claims
Per beneficiary
$3,350
$185.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $41,729,297 |
| 2021 | $50,336,999 |
| 2022 | $69,225,105 |
| 2023 | $93,684,777 |
| 2024 | $118,601,786 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antifungal Drug Use for Onychomycosis.
Thomas J, Peterson GM, Christenson JK, et al. · Am J Ther 2019 · Systematic Review
- Efinaconazole 10% solution in the treatment of onychomycosis of the toenails.
Joseph WS, Vlahovic TC, Pillai R, et al. · J Am Podiatr Med Assoc 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Topical Treatment of Onychomycosis and Clinically Meaningful Outcomes.
Gupta AK, Korotzer A · J Drugs Dermatol 2016 · Clinical Trial, Phase III, Multicenter Study
- Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early.
Rich P · J Drugs Dermatol 2015 · Multicenter Study, Randomized Controlled Trial
- Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis.
Gupta AK, Cooper EA · Skin Therapy Lett 2021 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants.
Lipner SR, Gupta AK, Vlahovic TC, et al. · J Drugs Dermatol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.